

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All Primary cancers

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		23558	2767	11.9	8504	36.6	1369	5.9	14818	64.0	895	3.8	3714	15.9
	Age at baseline	<18	5290	635	12.1	1770	33.9	59	1.1	3399	65.3	312	5.9	1041	19.8
		18-19	1964	254	13.0	705	36.5	33	1.7	1322	68.5	73	3.7	335	17.2
		20-24	5470	670	12.4	1906	35.3	175	3.2	3579	66.4	232	4.3	937	17.3
		25-29	5110	624	12.3	1976	39.2	410	8.1	3214	64.0	153	3.0	724	14.3
		30-34	3523	395	11.3	1363	39.4	411	11.8	2115	61.3	90	2.6	469	13.5
		35+	2201	189	8.7	784	36.3	281	13.0	1189	55.1	35	1.6	208	9.6
	Years since diagnosis	5-9	2383	278	11.8	820	35.1	118	5.0	1371	58.9	158	6.7	456	19.3
		10-14	7680	1113	14.6	2929	38.6	520	6.8	4930	65.2	303	4.0	1293	17.0
		15-19	7552	865	11.6	2766	37.2	434	5.8	4877	65.7	243	3.2	1261	16.9
		20+	5943	511	8.7	1989	34.0	297	5.0	3640	62.3	191	3.2	704	12.0
	Age at diagnosis	<1	1778	125	7.1	151	8.6	11	0.6	781	44.4	59	3.3	378	21.4
		1-4	7584	903	12.0	2886	38.6	53	0.7	5403	72.5	398	5.3	1306	17.3
		5-9	5282	631	12.1	2030	39.0	177	3.4	3493	67.2	198	3.8	788	15.0
		10-14	4993	672	13.6	2034	41.3	504	10.2	3067	62.4	169	3.4	730	14.8
		15-20	3921	436	11.3	1403	36.6	624	16.2	2074	54.2	71	1.8	512	13.3
Males	All cases		12463	1519	12.3	4617	37.6	697	5.6	7880	64.3	491	4.0	2016	16.3
	Age at baseline	<18	2841	339	12.0	937	33.5	40	1.4	1786	64.0	164	5.8	586	20.8
		18-19	1014	143	14.2	391	39.0	25	2.5	680	67.9	39	3.9	171	17.0
		20-24	2840	344	12.2	1015	36.2	109	3.9	1863	66.7	113	4.0	482	17.1
		25-29	2800	373	13.5	1127	40.9	206	7.4	1785	64.9	86	3.1	410	14.8
		30-34	1856	214	11.7	735	40.3	204	11.1	1136	62.4	61	3.3	256	14.0
		35+	1112	106	9.7	412	37.8	113	10.3	630	57.7	28	2.6	111	10.1
	Years since diagnosis	5-9	1326	154	11.7	454	35.0	66	5.0	732	56.7	83	6.3	258	19.7
		10-14	4084	614	15.2	1605	39.8	257	6.3	2641	65.7	162	4.0	711	17.5
		15-19	3918	464	12.0	1464	37.9	225	5.8	2572	66.8	135	3.5	678	17.5
		20+	3135	287	9.2	1094	35.4	149	4.8	1935	62.8	111	3.6	369	11.9
	Age at diagnosis	<1	901	60	6.7	66	7.4	4	0.4	381	42.8	28	3.1	198	22.1
		1-4	3934	499	12.8	1501	38.7	36	0.9	2762	71.4	207	5.3	703	18.0
		5-9	2955	367	12.5	1180	40.6	133	4.5	1967	67.9	108	3.7	438	15.0
		10-14	2603	339	13.1	1113	43.3	252	9.8	1646	64.1	99	3.8	384	14.9
		15-20	2070	254	12.5	757	37.3	272	13.3	1124	55.6	49	2.4	293	14.4
Females	All cases		11095	1248	11.4	3887	35.5	672	6.1	6938	63.6	404	3.7	1698	15.4
	Age at baseline	<18	2449	296	12.2	833	34.4	19	0.8	1613	66.8	148	6.1	455	18.6
		18-19	950	111	11.8	314	33.7	8	0.9	642	69.2	34	3.6	164	17.5
		20-24	2630	326	12.5	891	34.3	66	2.5	1716	66.2	119	4.6	455	17.4
		25-29	2310	251	11.0	849	37.2	204	8.9	1429	62.9	67	2.9	314	13.7
		30-34	1667	181	11.0	628	38.4	207	12.6	979	60.0	29	1.8	213	12.9
		35+	1089	83	7.7	372	34.9	168	15.7	559	52.5	7	0.7	97	9.1
	Years since diagnosis	5-9	1057	124	11.9	366	35.3	52	5.0	639	61.7	75	7.1	198	18.9
		10-14	3596	499	14.0	1324	37.3	263	7.4	2289	64.6	141	3.9	582	16.3
		15-19	3634	401	11.1	1302	36.3	209	5.8	2305	64.6	108	3.0	583	16.2
		20+	2808	224	8.1	895	32.4	148	5.3	1705	61.8	80	2.9	335	12.1
	Age at diagnosis	<1	877	65	7.5	85	9.7	7	0.8	400	46.1	31	3.6	180	20.6
		1-4	3650	404	11.2	1385	38.5	17	0.5	2641	73.6	191	5.3	603	16.6
		5-9	2327	264	11.4	850	36.9	44	1.9	1526	66.4	90	3.9	350	15.1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All Primary cancers

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	2390	333	14.1	921	39.1	252	10.6	1421	60.5	70	3.0	346	14.6
		15-20	1851	182	10.0	646	35.7	352	19.4	950	52.7	22	1.2	219	12.0

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All leukemias

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		7245	1705	23.8	5174	73.0	17	0.2	5561	78.4	672	9.3	1506	21.0
	Age at baseline	<18	2096	474	22.9	1499	73.3	6	0.3	1602	78.3	219	10.5	481	23.1
		18-19	769	188	24.6	560	74.6	2	0.3	604	80.4	55	7.2	143	18.7
		20-24	1788	429	24.2	1316	75.0	5	0.3	1413	80.4	191	10.7	348	19.6
		25-29	1459	352	24.3	1029	71.7	3	0.2	1111	77.3	119	8.2	298	20.6
		30-34	761	176	23.7	514	70.1	1	0.1	560	76.1	62	8.3	157	21.0
		35+	372	86	23.4	256	70.3	.	.	271	74.2	26	7.1	79	21.6
	Years since diagnosis	5-9	904	180	20.2	557	63.4	1	0.1	592	67.3	111	12.4	194	21.6
		10-14	2445	674	27.9	1853	77.5	6	0.2	1967	82.2	234	9.6	586	24.2
		15-19	2236	538	24.3	1614	73.6	7	0.3	1753	79.9	187	8.4	424	19.1
		20+	1660	313	19.1	1150	70.9	3	0.2	1249	76.8	140	8.5	302	18.4
	Age at diagnosis	<1	232	77	33.8	117	51.5	1	0.4	161	70.6	19	8.3	129	56.1
		1-4	3421	710	20.9	2522	75.3	10	0.3	2692	80.4	314	9.2	610	17.9
		5-9	1754	396	22.9	1273	74.4	4	0.2	1353	78.9	158	9.1	321	18.5
		10-14	1203	362	30.3	851	72.0	2	0.2	917	77.3	132	11.0	290	24.3
		15-20	635	160	25.8	411	66.8	.	.	438	71.1	49	7.9	156	25.1
Males	All cases		3827	930	24.6	2671	71.4	10	0.3	2883	77.0	366	9.7	798	21.0
	Age at baseline	<18	1136	253	22.5	760	68.8	3	0.3	814	73.7	119	10.5	254	22.5
		18-19	411	108	26.3	287	70.9	2	0.5	311	76.8	27	6.6	83	20.2
		20-24	891	213	24.1	645	73.6	2	0.2	700	79.9	94	10.6	169	19.1
		25-29	783	207	26.8	558	72.8	2	0.3	602	78.4	66	8.5	158	20.4
		30-34	397	91	23.6	269	70.4	1	0.3	297	77.5	39	10.1	87	22.5
		35+	209	58	28.0	152	74.1	.	.	159	77.2	21	10.2	47	22.8
	Years since diagnosis	5-9	510	101	19.9	287	58.0	.	.	305	61.6	56	11.1	103	20.3
		10-14	1301	368	28.7	967	76.1	3	0.2	1026	80.7	126	9.8	314	24.3
		15-19	1136	281	25.0	804	72.4	5	0.4	886	79.6	101	9.0	224	19.9
		20+	880	180	20.7	613	71.1	2	0.2	666	77.2	83	9.5	157	18.0
	Age at diagnosis	<1	110	36	33.6	56	52.8	.	.	79	74.5	11	10.2	59	54.6
		1-4	1809	392	21.9	1267	71.4	6	0.3	1362	76.8	167	9.3	332	18.5
		5-9	935	223	24.2	665	73.1	3	0.3	709	77.9	84	9.1	166	18.0
		10-14	588	178	30.5	425	73.8	1	0.2	460	79.6	70	12.0	142	24.4
		15-20	385	101	26.9	258	69.2	.	.	273	73.0	34	9.0	99	26.2
Females	All cases		3418	775	22.9	2503	74.8	7	0.2	2678	79.9	306	9.0	708	20.8
	Age at baseline	<18	960	221	23.3	739	78.5	3	0.3	788	83.7	100	10.4	227	23.7
		18-19	358	80	22.6	273	78.9	.	.	293	84.7	28	7.9	60	16.9
		20-24	897	216	24.3	671	76.3	3	0.3	713	80.9	97	10.9	179	20.1
		25-29	676	145	21.5	471	70.4	1	0.1	509	76.0	53	7.9	140	20.8
		30-34	364	85	23.7	245	69.8	.	.	263	74.5	23	6.4	70	19.4
		35+	163	28	17.4	104	65.4	.	.	112	70.4	5	3.1	32	20.0
	Years since diagnosis	5-9	394	79	20.6	270	70.5	1	0.3	287	74.7	55	14.0	91	23.3
		10-14	1144	306	27.0	886	79.0	3	0.3	941	83.9	108	9.5	272	23.9
		15-19	1100	257	23.5	810	74.9	2	0.2	867	80.2	86	7.8	200	18.2
		20+	780	133	17.2	537	70.7	1	0.1	583	76.4	57	7.4	145	18.8
	Age at diagnosis	<1	122	41	33.9	61	50.4	1	0.8	82	67.2	8	6.6	70	57.4
		1-4	1612	318	19.9	1255	79.7	4	0.2	1330	84.5	147	9.2	278	17.3
		5-9	819	173	21.4	608	75.8	1	0.1	644	80.1	74	9.1	155	19.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All leukemias

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	615	184	30.1	426	70.3	1	0.2	457	75.2	62	10.1	148	24.2
		15-20	250	59	24.1	153	63.2	.	.	165	68.2	15	6.1	57	23.4

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		6067	1324	22.0	4859	81.9	15	0.2	5137	86.5	655	10.9	854	14.2
	Age at baseline	<18	1812	374	20.9	1440	81.4	5	0.3	1491	84.3	213	11.8	290	16.1
		18-19	666	153	23.1	536	82.6	2	0.3	561	86.4	54	8.2	91	13.7
		20-24	1524	335	22.2	1244	83.0	4	0.3	1317	87.9	185	12.2	196	12.9
		25-29	1207	267	22.3	959	80.7	3	0.2	1028	86.3	117	9.8	162	13.5
		30-34	590	132	22.8	461	81.0	1	0.2	504	88.3	61	10.5	78	13.4
		35+	268	63	23.8	219	83.6	.	.	236	90.1	25	9.5	37	14.0
	Years since diagnosis	5-9	777	145	19.0	530	70.2	1	0.1	546	72.3	104	13.5	127	16.5
		10-14	2049	546	26.9	1761	87.7	5	0.2	1836	91.5	229	11.2	360	17.7
		15-19	1847	408	22.3	1509	83.4	7	0.4	1613	89.1	186	10.1	202	11.0
		20+	1394	225	16.3	1059	77.6	2	0.1	1142	83.5	136	9.8	165	11.9
	Age at diagnosis	<1	127	36	28.8	98	79.0	1	0.8	115	92.0	16	12.7	53	42.1
		1-4	3030	573	19.1	2417	81.6	8	0.3	2528	85.3	309	10.2	369	12.2
		5-9	1537	311	20.5	1217	80.9	4	0.3	1284	85.4	155	10.2	197	12.9
		10-14	940	282	30.1	780	84.0	2	0.2	834	89.6	128	13.6	155	16.5
		15-20	433	122	29.0	347	83.4	.	.	376	90.4	47	11.2	80	19.0
Males	All cases		3231	738	23.1	2514	79.5	9	0.3	2674	84.5	356	11.1	464	14.5
	Age at baseline	<18	982	201	20.7	729	76.4	2	0.2	759	79.6	116	11.9	149	15.3
		18-19	359	87	24.3	276	78.2	2	0.6	289	81.9	27	7.5	52	14.5
		20-24	759	172	22.8	607	81.0	2	0.3	649	86.8	89	11.8	96	12.7
		25-29	660	165	25.2	526	81.0	2	0.3	564	86.8	65	9.9	91	13.9
		30-34	313	68	22.4	244	80.8	1	0.3	269	88.8	39	12.8	52	17.0
		35+	158	45	28.7	132	84.6	.	.	144	92.3	20	12.8	24	15.4
	Years since diagnosis	5-9	440	84	19.2	272	63.7	.	.	284	66.5	52	12.0	67	15.3
		10-14	1099	301	27.7	922	85.8	2	0.2	957	89.1	122	11.2	192	17.6
		15-19	949	217	23.1	753	81.0	5	0.5	816	87.6	101	10.8	118	12.6
		20+	743	136	18.5	567	77.6	2	0.3	617	84.3	81	11.0	87	11.8
	Age at diagnosis	<1	63	15	24.2	49	80.3	.	.	58	95.1	10	16.1	26	41.9
		1-4	1591	319	20.2	1213	77.8	5	0.3	1276	81.8	164	10.4	190	12.0
		5-9	829	184	22.5	639	78.9	3	0.4	680	84.0	83	10.1	111	13.5
		10-14	476	142	29.9	393	83.4	1	0.2	424	89.8	67	14.1	82	17.3
		15-20	272	78	29.5	220	84.0	.	.	236	90.1	32	12.1	55	20.8
Females	All cases		2836	586	20.9	2345	84.6	6	0.2	2463	88.8	299	10.6	390	13.8
	Age at baseline	<18	830	173	21.1	711	87.3	3	0.4	732	89.9	97	11.7	141	17.0
		18-19	307	66	21.7	260	87.8	.	.	272	91.9	27	8.9	39	12.8
		20-24	765	163	21.5	637	84.9	2	0.3	668	89.1	96	12.6	100	13.2
		25-29	547	102	18.7	433	80.2	1	0.2	464	85.8	52	9.6	71	13.0
		30-34	277	64	23.4	217	81.3	.	.	235	87.7	22	8.0	26	9.5
		35+	110	18	16.7	87	82.1	.	.	92	86.8	5	4.6	13	12.0
	Years since diagnosis	5-9	337	61	18.6	258	78.7	1	0.3	262	79.9	52	15.5	60	17.9
		10-14	950	245	26.0	839	90.0	3	0.3	879	94.3	107	11.3	168	17.8
		15-19	898	191	21.4	756	85.9	2	0.2	797	90.6	85	9.5	84	9.4
		20+	651	89	13.8	492	77.7	.	.	525	82.7	55	8.5	78	12.1
	Age at diagnosis	<1	64	21	33.3	49	77.8	1	1.6	57	89.1	6	9.4	27	42.2
		1-4	1439	254	17.8	1204	85.8	3	0.2	1252	89.2	145	10.1	179	12.5
		5-9	708	127	18.2	578	83.3	1	0.1	604	87.0	72	10.2	86	12.2
		10-14	464	140	30.2	387	84.5	1	0.2	410	89.3	61	13.2	73	15.8
		15-20	161	44	28.0	127	82.5	.	.	140	90.9	15	9.6	25	15.9

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
		All cases	N	%	N	%	N	%	N	%	N	%	N	%	
Both sexes	All cases	871	332	38.6	185	21.7	2	0.2	315	36.9	7	0.8	578	67.1	
	Age at baseline	<18	225	94	42.3	37	16.9	1	0.4	90	41.1	3	1.3	172	77.1
		18-19	82	28	34.6	16	19.8	.	.	35	43.2	1	1.2	46	56.8
		20-24	191	75	39.5	38	20.4	1	0.5	62	33.2	3	1.6	135	71.1
		25-29	186	77	41.8	45	24.3	.	.	65	35.1	.	.	117	63.6
		30-34	118	40	34.8	30	26.3	.	.	39	34.2	.	.	71	61.2
		35+	69	18	26.5	19	28.4	.	.	24	35.3	.	.	37	55.2
	Years since diagnosis	5-9	81	31	38.8	15	19.2	.	.	36	46.2	4	5.0	58	72.5
		10-14	307	117	38.6	54	17.9	1	0.3	106	35.1	2	0.7	203	66.8
		15-19	301	110	36.8	72	24.2	.	.	105	35.2	.	.	199	66.3
		20+	182	74	41.6	44	25.0	1	0.6	68	38.6	1	0.6	118	66.7
	Age at diagnosis	<1	90	39	43.8	14	15.7	.	.	41	46.1	3	3.4	69	77.5
		1-4	299	117	39.7	59	20.1	2	0.7	116	39.5	1	0.3	215	72.6
		5-9	163	70	43.2	32	20.4	.	.	46	29.1	2	1.2	110	67.9
		10-14	182	76	42.7	42	23.7	.	.	67	37.9	.	.	116	65.2
		15-20	137	30	22.1	38	28.1	.	.	45	33.1	1	0.7	68	50.0
Males	All cases	427	154	36.7	79	19.0	1	0.2	140	33.7	3	0.7	291	69.1	
	Age at baseline	<18	122	48	40.0	17	14.3	1	0.8	42	35.3	1	0.8	95	79.2
		18-19	42	16	38.1	8	19.0	.	.	18	42.9	.	.	27	64.3
		20-24	92	28	30.4	18	20.2	.	.	29	32.6	2	2.2	61	66.3
		25-29	82	35	43.8	17	21.0	.	.	26	32.1	.	.	56	70.0
		30-34	56	19	35.2	12	22.6	.	.	18	34.0	.	.	32	58.2
		35+	33	8	25.0	7	22.6	.	.	7	21.9	.	.	20	62.5
	Years since diagnosis	5-9	47	14	29.8	8	17.8	.	.	15	33.3	2	4.3	31	66.0
		10-14	152	58	38.9	21	14.0	1	0.7	53	35.3	1	0.7	110	73.8
		15-19	141	50	35.7	34	24.6	.	.	49	35.3	.	.	93	66.0
		20+	87	32	38.1	16	19.5	.	.	23	28.0	.	.	57	67.9
	Age at diagnosis	<1	39	19	50.0	5	13.2	.	.	18	47.4	1	2.6	29	76.3
		1-4	165	58	35.6	28	17.2	1	0.6	57	35.0	.	.	124	76.1
		5-9	75	29	39.2	13	18.3	.	.	16	22.5	1	1.4	47	63.5
		10-14	74	32	44.4	14	19.7	.	.	24	33.8	.	.	53	73.6
		15-20	74	16	21.9	19	26.4	.	.	25	34.2	1	1.4	38	51.4
Females	All cases	444	178	40.5	106	24.3	1	0.2	175	40.0	4	0.9	287	65.2	
	Age at baseline	<18	103	46	45.1	20	20.0	.	.	48	48.0	2	1.9	77	74.8
		18-19	40	12	30.8	8	20.5	.	.	17	43.6	1	2.6	19	48.7
		20-24	99	47	48.0	20	20.6	1	1.0	33	33.7	1	1.0	74	75.5
		25-29	104	42	40.4	28	26.9	.	.	39	37.5	.	.	61	58.7
		30-34	62	21	34.4	18	29.5	.	.	21	34.4	.	.	39	63.9
		35+	36	10	27.8	12	33.3	.	.	17	47.2	.	.	17	48.6
	Years since diagnosis	5-9	34	17	51.5	7	21.2	.	.	21	63.6	2	6.1	27	81.8
		10-14	155	59	38.3	33	21.9	.	.	53	34.9	1	0.6	93	60.0
		15-19	160	60	37.7	38	23.9	.	.	56	35.2	.	.	106	66.7
		20+	95	42	44.7	28	29.8	1	1.1	45	47.9	1	1.1	61	65.6
	Age at diagnosis	<1	51	20	39.2	9	17.6	.	.	23	45.1	2	3.9	40	78.4
		1-4	134	59	44.7	31	23.7	1	0.8	59	45.0	1	0.8	91	68.4
		5-9	88	41	46.6	19	22.1	.	.	30	34.5	1	1.1	63	71.6
		10-14	108	44	41.5	28	26.4	.	.	43	40.6	.	.	63	59.4
		15-20	63	14	22.2	19	30.2	.	.	20	31.7	.	.	30	48.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4184	282	6.8	189	4.6	6	0.1	1236	30.1	10	0.2	405	9.8
	Age at baseline	<18	891	64	7.3	54	6.1	3	0.3	338	38.3	3	0.3	130	14.7
		18-19	349	23	6.8	14	4.1	.	.	128	38.1	1	0.3	53	15.6
		20-24	1093	71	6.6	48	4.5	.	.	341	31.8	4	0.4	123	11.4
		25-29	1021	69	6.8	54	5.4	3	0.3	286	28.5	1	0.1	59	5.9
		30-34	581	35	6.1	14	2.4	.	.	110	19.2	1	0.2	32	5.5
		35+	249	20	8.2	5	2.1	.	.	33	13.6	.	.	8	3.3
	Years since diagnosis	5-9	428	29	6.9	39	9.3	.	.	147	35.2	3	0.7	60	14.3
		10-14	1424	90	6.4	44	3.1	5	0.4	432	30.7	.	.	107	7.6
		15-19	1325	103	7.9	62	4.8	1	0.1	393	30.3	6	0.5	169	13.0
		20+	1007	60	6.0	44	4.4	.	.	264	26.6	1	0.1	69	6.9
	Age at diagnosis	<1	205	13	6.4	14	6.9	1	0.5	102	50.0	1	0.5	47	23.0
		1-4	1223	82	6.8	57	4.7	1	0.1	441	36.8	5	0.4	187	15.5
		5-9	1326	92	7.0	71	5.4	1	0.1	402	30.9	3	0.2	97	7.4
		10-14	996	69	7.0	36	3.7	3	0.3	228	23.2	1	0.1	57	5.8
		15-20	434	26	6.1	11	2.6	.	.	63	15.0	.	.	17	4.0
Males	All cases		2276	165	7.4	106	4.7	3	0.1	726	32.6	5	0.2	232	10.4
	Age at baseline	<18	494	38	7.8	31	6.4	1	0.2	200	41.1	1	0.2	83	17.0
		18-19	176	14	8.2	6	3.5	.	.	67	39.4	1	0.6	25	14.5
		20-24	584	41	7.1	28	4.9	.	.	206	35.9	2	0.3	75	13.0
		25-29	579	47	8.2	30	5.2	2	0.3	178	31.3	1	0.2	28	4.9
		30-34	309	16	5.2	7	2.3	.	.	53	17.6	.	.	16	5.2
		35+	134	9	7.0	4	3.1	.	.	22	17.2	.	.	5	3.9
	Years since diagnosis	5-9	242	18	7.6	22	9.3	.	.	80	34.0	1	0.4	36	15.3
		10-14	766	54	7.1	30	4.0	2	0.3	261	34.5	.	.	63	8.3
		15-19	720	58	8.2	31	4.4	1	0.1	240	34.1	4	0.6	98	13.9
		20+	548	35	6.5	23	4.3	.	.	145	27.1	.	.	35	6.5
	Age at diagnosis	<1	121	10	8.3	5	4.2	.	.	60	50.0	.	.	31	25.8
		1-4	647	47	7.4	31	4.9	.	.	248	39.1	3	0.5	106	16.6
		5-9	738	61	8.4	41	5.6	1	0.1	251	34.7	2	0.3	58	8.0
		10-14	526	38	7.3	24	4.6	2	0.4	128	24.7	.	.	28	5.4
		15-20	244	9	3.8	5	2.1	.	.	39	16.7	.	.	9	3.8
Females	All cases		1908	117	6.2	83	4.4	3	0.2	510	27.1	5	0.3	173	9.2
	Age at baseline	<18	397	26	6.6	23	5.8	2	0.5	138	34.9	2	0.5	47	11.9
		18-19	173	9	5.4	8	4.8	.	.	61	36.7	.	.	28	16.7
		20-24	509	30	6.0	20	4.0	.	.	135	27.0	2	0.4	48	9.6
		25-29	442	22	5.1	24	5.5	1	0.2	108	24.8	.	.	31	7.1
		30-34	272	19	7.0	7	2.6	.	.	57	21.0	1	0.4	16	5.9
		35+	115	11	9.6	1	0.9	.	.	11	9.6	.	.	3	2.6
	Years since diagnosis	5-9	186	11	6.0	17	9.3	.	.	67	36.6	2	1.1	24	13.0
		10-14	658	36	5.5	14	2.1	3	0.5	171	26.3	.	.	44	6.8
		15-19	605	45	7.6	31	5.2	.	.	153	25.8	2	0.3	71	11.9
		20+	459	25	5.5	21	4.6	.	.	119	26.1	1	0.2	34	7.4
	Age at diagnosis	<1	84	3	3.6	9	10.7	1	1.2	42	50.0	1	1.2	16	19.0
		1-4	576	35	6.2	26	4.6	1	0.2	193	34.2	2	0.4	81	14.2
		5-9	588	31	5.3	30	5.2	.	.	151	26.0	1	0.2	39	6.7
		10-14	470	31	6.7	12	2.6	1	0.2	100	21.5	1	0.2	29	6.2
		15-20	190	17	9.0	6	3.2	.	.	24	12.8	.	.	8	4.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Astrocytomas

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2509	131	5.3	59	2.4	2	0.1	420	17.0	7	0.3	89	3.6
	Age at baseline	<18	493	26	5.3	17	3.5	2	0.4	133	27.1	2	0.4	32	6.5
		18-19	202	9	4.6	6	3.0	.	.	54	27.8	.	.	11	5.6
		20-24	662	38	5.8	16	2.4	.	.	106	16.3	3	0.5	30	4.6
		25-29	629	32	5.2	13	2.1	.	.	84	13.6	1	0.2	14	2.3
		30-34	357	16	4.5	5	1.4	.	.	32	9.1	1	0.3	2	0.6
		35+	166	10	6.1	2	1.2	.	.	11	6.7
	Years since diagnosis	5-9	219	10	4.6	14	6.5	.	.	50	23.0	2	0.9	14	6.5
		10-14	838	46	5.5	13	1.6	2	0.2	156	18.9	.	.	19	2.3
		15-19	778	48	6.3	17	2.2	.	.	119	15.6	4	0.5	36	4.7
		20+	674	27	4.0	15	2.2	.	.	95	14.3	1	0.1	20	3.0
	Age at diagnosis	<1	144	10	6.9	9	6.3	1	0.7	68	47.2	1	0.7	24	16.7
		1-4	741	34	4.7	16	2.2	.	.	166	22.8	2	0.3	41	5.6
		5-9	750	34	4.6	18	2.4	1	0.1	98	13.3	3	0.4	15	2.0
		10-14	599	37	6.2	11	1.9	.	.	60	10.1	1	0.2	7	1.2
		15-20	275	16	5.9	5	1.9	.	.	28	10.4	.	.	2	0.7
Males	All cases		1302	73	5.7	31	2.4	1	0.1	243	18.9	3	0.2	51	4.0
	Age at baseline	<18	258	15	5.9	11	4.3	1	0.4	78	30.6	.	.	22	8.6
		18-19	102	5	5.0	3	3.0	.	.	31	31.3	.	.	5	5.0
		20-24	325	18	5.6	7	2.2	.	.	62	19.3	2	0.6	19	5.9
		25-29	351	23	6.6	7	2.0	.	.	52	15.0	1	0.3	4	1.2
		30-34	178	7	4.0	1	0.6	.	.	12	6.9	.	.	1	0.6
		35+	88	5	5.8	2	2.3	.	.	8	9.3
	Years since diagnosis	5-9	117	4	3.4	7	6.0	.	.	27	23.1	.	.	7	6.0
		10-14	437	26	6.0	11	2.5	1	0.2	97	22.5	.	.	14	3.2
		15-19	391	27	7.0	7	1.8	.	.	68	17.7	3	0.8	18	4.7
		20+	357	16	4.5	6	1.7	.	.	51	14.5	.	.	12	3.4
	Age at diagnosis	<1	81	8	9.9	4	4.9	.	.	40	49.4	.	.	19	23.5
		1-4	373	19	5.2	9	2.4	.	.	92	25.1	1	0.3	24	6.5
		5-9	394	23	5.9	9	2.3	1	0.3	62	16.0	2	0.5	5	1.3
		10-14	302	17	5.7	7	2.3	.	.	31	10.4	.	.	2	0.7
		15-20	152	6	4.0	2	1.3	.	.	18	12.1	.	.	1	0.7
Females	All cases		1207	58	4.9	28	2.3	1	0.1	177	14.9	4	0.3	38	3.2
	Age at baseline	<18	235	11	4.7	6	2.6	1	0.4	55	23.4	2	0.9	10	4.3
		18-19	100	4	4.1	3	3.1	.	.	23	24.2	.	.	6	6.2
		20-24	337	20	6.0	9	2.7	.	.	44	13.3	1	0.3	11	3.3
		25-29	278	9	3.3	6	2.2	.	.	32	11.7	.	.	10	3.6
		30-34	179	9	5.0	4	2.2	.	.	20	11.2	1	0.6	1	0.6
		35+	78	5	6.4	3	3.8
	Years since diagnosis	5-9	102	6	6.0	7	7.0	.	.	23	23.0	2	2.0	7	7.0
		10-14	401	20	5.0	2	0.5	1	0.3	59	14.9	.	.	5	1.3
		15-19	387	21	5.5	10	2.6	.	.	51	13.5	1	0.3	18	4.7
		20+	317	11	3.5	9	2.9	.	.	44	14.0	1	0.3	8	2.5
	Age at diagnosis	<1	63	2	3.2	5	7.9	1	1.6	28	44.4	1	1.6	5	7.9
		1-4	368	15	4.1	7	1.9	.	.	74	20.6	1	0.3	17	4.7
		5-9	356	11	3.1	9	2.5	.	.	36	10.2	1	0.3	10	2.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Astrocytomas

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	297	20	6.8	4	1.4	.	.	29	9.9	1	0.3	5	1.7
		15-20	123	10	8.3	3	2.5	.	.	10	8.3	.	.	1	0.8

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Medulloblastoma/PNET

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
		All cases	N	%	N	%	N	%	N	%	N	%	N	%	
Both sexes	All cases	979	106	11.0	99	10.3	1	0.1	661	68.9	3	0.3	217	22.5	
	Age at baseline	<18	233	23	10.0	26	11.4	.	.	153	66.8	1	0.4	62	27.0
		18-19	77	9	12.2	5	6.8	.	.	52	70.3	1	1.4	23	31.1
		20-24	273	28	10.4	25	9.3	.	.	201	74.7	1	0.4	68	25.2
		25-29	236	30	12.8	31	13.3	1	0.4	169	72.8	.	.	34	14.6
		30-34	126	14	11.2	9	7.3	.	.	70	56.9	.	.	25	20.0
		35+	34	2	6.3	3	9.4	.	.	16	50.0	.	.	5	15.6
	Years since diagnosis	5-9	119	14	12.3	19	16.8	.	.	73	64.0	1	0.9	32	27.8
		10-14	333	31	9.4	23	7.0	1	0.3	236	71.5	.	.	62	18.8
		15-19	323	40	12.5	39	12.3	.	.	217	68.7	2	0.6	86	27.0
		20+	204	21	10.4	18	9.0	.	.	135	67.8	.	.	37	18.4
	Age at diagnosis	<1	23	1	4.5	2	9.1	.	.	17	77.3	.	.	14	63.6
		1-4	279	31	11.3	26	9.5	.	.	197	72.2	3	1.1	86	31.3
		5-9	402	49	12.3	44	11.1	.	.	272	68.7	.	.	69	17.3
		10-14	217	21	9.8	23	10.8	1	0.5	148	69.2	.	.	36	16.8
		15-20	58	4	7.3	4	7.4	.	.	27	50.0	.	.	12	21.8
Males	All cases	599	68	11.6	60	10.3	.	.	404	69.3	2	0.3	136	23.2	
	Age at baseline	<18	141	15	10.9	15	10.9	.	.	91	65.9	1	0.7	39	28.3
		18-19	43	5	12.2	2	5.0	.	.	28	68.3	1	2.4	14	34.1
		20-24	177	19	10.9	18	10.3	.	.	131	75.3	.	.	48	27.4
		25-29	145	20	13.9	17	11.9	.	.	110	77.5	.	.	19	13.3
		30-34	71	7	10.0	6	8.8	.	.	35	51.5	.	.	13	18.6
		35+	22	2	10.0	2	10.0	.	.	9	45.0	.	.	3	15.0
	Years since diagnosis	5-9	72	11	16.2	12	17.9	.	.	39	57.4	1	1.5	22	32.4
		10-14	196	20	10.3	15	7.7	.	.	145	74.7	.	.	37	19.1
		15-19	207	22	10.7	21	10.3	.	.	141	69.8	1	0.5	58	28.4
		20+	124	15	12.4	12	10.1	.	.	79	66.4	.	.	19	15.7
	Age at diagnosis	<1	16	.	.	1	6.7	.	.	11	73.3	.	.	7	46.7
		1-4	168	19	11.5	15	9.1	.	.	119	73.0	2	1.2	53	32.1
		5-9	257	32	12.5	27	10.6	.	.	175	69.2	.	.	49	19.3
		10-14	123	16	13.2	15	12.5	.	.	84	69.4	.	.	21	17.4
		15-20	35	1	3.1	2	6.5	.	.	15	48.4	.	.	6	18.8
Females	All cases	380	38	10.1	39	10.4	1	0.3	257	68.4	1	0.3	81	21.5	
	Age at baseline	<18	92	8	8.8	11	12.1	.	.	62	68.1	.	.	23	25.0
		18-19	34	4	12.1	3	9.1	.	.	24	72.7	.	.	9	27.3
		20-24	96	9	9.5	7	7.4	.	.	70	73.7	1	1.1	20	21.1
		25-29	91	10	11.1	14	15.6	1	1.1	59	65.6	.	.	15	16.7
		30-34	55	7	12.7	3	5.5	.	.	35	63.6	.	.	12	21.8
		35+	12	.	.	1	8.3	.	.	7	58.3	.	.	2	16.7
	Years since diagnosis	5-9	47	3	6.5	7	15.2	.	.	34	73.9	.	.	10	21.3
		10-14	137	11	8.1	8	5.9	1	0.7	91	66.9	.	.	25	18.4
		15-19	116	18	15.8	18	15.8	.	.	76	66.7	1	0.9	28	24.6
		20+	80	6	7.5	6	7.5	.	.	56	70.0	.	.	18	22.5
	Age at diagnosis	<1	7	1	14.3	1	14.3	.	.	6	85.7	.	.	7	.
		1-4	111	12	10.9	11	10.0	.	.	78	70.9	1	0.9	33	30.0
		5-9	145	17	11.9	17	11.9	.	.	97	67.8	.	.	20	13.9

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

**Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins:
Medulloblastoma/PNET**

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	94	5	5.4	8	8.6	1	1.1	64	68.8	.	.	15	16.1
		15-20	23	3	13.0	2	8.7	.	.	12	52.2	.	.	6	26.1

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Hodgkin

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2827	140	5.0	1547	56.0	1298	46.7	1640	59.4	5	0.2	227	8.1
	Age at baseline	<18	55	3	5.5	31	57.4	30	56.6	31	58.5	.	.	4	7.3
		18-19	55	1	1.8	31	56.4	29	52.7	33	60.0	.	.	4	7.3
		20-24	328	18	5.6	196	61.3	162	50.5	216	67.5	.	.	33	10.2
		25-29	733	37	5.1	461	64.4	397	55.0	452	63.2	2	0.3	63	8.7
		30-34	862	47	5.5	475	56.5	404	47.8	510	60.7	1	0.1	86	10.1
		35+	794	34	4.3	353	45.4	276	35.3	398	51.2	2	0.3	37	4.7
	Years since diagnosis	5-9	221	16	7.4	106	49.8	111	51.9	105	49.3	1	0.5	19	8.8
		10-14	867	53	6.2	508	59.8	486	57.0	526	62.0	1	0.1	85	9.9
		15-19	930	30	3.3	542	59.6	413	45.3	560	61.7	2	0.2	97	10.6
		20+	809	41	5.1	391	49.4	288	36.1	449	56.8	1	0.1	26	3.3
	Age at diagnosis	1-4	71	1	1.4	39	55.7	27	38.6	45	64.3	.	.	3	4.3
		5-9	353	12	3.4	212	60.9	167	47.9	222	64.0	.	.	23	6.6
		10-14	1026	59	5.8	632	62.9	489	48.4	680	67.7	1	0.1	83	8.2
		15-20	1377	68	5.0	664	49.5	615	45.7	693	51.8	4	0.3	118	8.7
Males	All cases		1458	74	5.1	791	55.4	660	46.0	831	58.2	3	0.2	121	8.4
	Age at baseline	<18	42	1	2.4	21	51.2	24	60.0	22	55.0	.	.	2	4.8
		18-19	44	1	2.3	25	56.8	23	52.3	26	59.1	.	.	3	6.8
		20-24	207	9	4.5	122	60.7	104	51.5	131	65.2	.	.	18	8.9
		25-29	401	24	6.1	243	62.1	198	50.0	238	60.9	1	0.3	38	9.6
		30-34	429	26	6.1	235	55.6	202	47.6	249	58.9	1	0.2	47	11.1
		35+	335	13	3.9	145	44.1	109	33.0	165	50.2	1	0.3	13	3.9
	Years since diagnosis	5-9	126	9	7.3	60	49.2	62	50.4	58	47.5	.	.	13	10.6
		10-14	441	28	6.4	252	58.2	239	54.9	260	60.2	1	0.2	44	10.1
		15-19	492	20	4.1	282	58.6	216	44.7	295	61.3	1	0.2	56	11.6
		20+	399	17	4.3	197	50.1	143	36.2	218	55.5	1	0.3	8	2.0
	Age at diagnosis	1-4	52	1	2.0	29	56.9	22	43.1	32	62.7	.	.	1	2.0
		5-9	259	4	1.6	155	61.0	126	49.4	157	62.1	.	.	14	5.4
		10-14	522	34	6.6	310	60.4	246	47.8	336	65.5	1	0.2	46	8.9
		15-20	625	35	5.7	297	48.6	266	43.3	306	50.1	2	0.3	60	9.7
Females	All cases		1369	66	4.9	756	56.6	638	47.6	809	60.7	2	0.1	106	7.9
	Age at baseline	<18	13	2	15.4	10	76.9	6	46.2	9	69.2	.	.	2	15.4
		18-19	11	.	.	6	54.5	6	54.5	7	63.6	.	.	1	9.1
		20-24	121	9	7.5	74	62.2	58	48.7	85	71.4	.	.	15	12.5
		25-29	332	13	4.0	218	67.1	199	61.0	214	66.0	1	0.3	25	7.6
		30-34	433	21	5.0	240	57.4	202	48.0	261	62.6	.	.	39	9.2
		35+	459	21	4.6	208	46.3	167	37.0	233	52.0	1	0.2	24	5.3
	Years since diagnosis	5-9	95	7	7.4	46	50.5	49	53.8	47	51.6	1	1.1	6	6.4
		10-14	426	25	6.0	256	61.4	247	59.1	266	63.8	.	.	41	9.8
		15-19	438	10	2.3	260	60.7	197	45.9	265	62.2	1	0.2	41	9.5
		20+	410	24	5.9	194	48.6	145	36.0	231	58.0	.	.	18	4.5
	Age at diagnosis	1-4	19	.	.	10	52.6	5	26.3	13	68.4	.	.	2	10.5
		5-9	94	8	8.5	57	60.6	41	43.6	65	69.1	.	.	9	9.6
		10-14	504	25	5.0	322	65.4	243	49.0	344	70.1	.	.	37	7.4
		15-20	752	33	4.5	367	50.3	349	47.7	387	53.2	2	0.3	58	7.9

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1915	251	13.2	1518	80.4	24	1.3	1746	92.5	83	4.4	338	17.8
	Age at baseline	<18	200	16	8.0	168	85.3	3	1.5	175	88.8	11	5.5	34	17.1
		18-19	119	15	12.7	96	81.4	1	0.8	109	92.4	7	5.9	23	19.5
		20-24	405	62	15.3	327	81.5	6	1.5	377	94.0	13	3.2	73	18.1
		25-29	526	73	14.0	417	81.0	6	1.2	485	94.0	21	4.0	99	19.0
		30-34	438	65	14.9	344	79.1	5	1.1	409	94.0	24	5.5	82	18.8
		35+	227	20	9.0	166	75.1	3	1.3	191	86.4	7	3.1	27	12.1
	Years since diagnosis	5-9	132	10	7.6	104	79.4	.	.	108	82.4	11	8.3	20	15.2
		10-14	609	100	16.5	503	83.7	9	1.5	560	93.2	22	3.6	110	18.2
		15-19	657	98	15.0	529	81.5	12	1.8	623	96.0	26	4.0	145	22.2
		20+	517	43	8.4	382	75.5	3	0.6	455	89.7	24	4.7	63	12.3
	Age at diagnosis	<1	12	1	8.3	9	75.0	1	8.3	8	66.7	.	.	1	8.3
		1-4	315	33	10.6	247	80.7	6	1.9	287	93.5	15	4.8	65	20.8
		5-9	579	68	11.8	457	79.6	3	0.5	536	93.4	21	3.6	98	17.0
		10-14	602	81	13.5	502	84.1	7	1.2	564	94.5	32	5.3	100	16.7
		15-20	407	68	16.9	303	76.1	7	1.7	351	88.2	15	3.7	74	18.4
Males	All cases		1290	155	12.1	1012	79.4	9	0.7	1173	92.0	60	4.7	220	17.2
	Age at baseline	<18	138	8	5.8	118	87.4	1	0.7	122	90.4	10	7.3	26	19.0
		18-19	87	10	11.6	70	81.4	.	.	79	91.9	4	4.7	13	15.1
		20-24	264	40	15.2	213	81.0	2	0.8	247	93.9	10	3.8	46	17.4
		25-29	367	49	13.5	288	79.8	3	0.8	340	93.9	11	3.0	71	19.5
		30-34	286	38	13.3	216	76.1	1	0.4	262	92.3	19	6.7	47	16.5
		35+	148	10	6.8	107	73.8	2	1.4	123	84.8	6	4.1	17	11.6
	Years since diagnosis	5-9	99	8	8.1	80	81.6	.	.	83	84.7	11	11.1	15	15.2
		10-14	413	62	15.1	344	84.1	4	1.0	380	92.9	16	3.9	74	18.0
		15-19	426	58	13.7	339	80.1	3	0.7	407	96.2	16	3.8	90	21.2
		20+	352	27	7.8	249	72.4	2	0.6	303	87.8	17	4.9	41	11.8
	Age at diagnosis	<1	3	.	.	1	33.3	.	.	1	33.3
		1-4	211	20	9.6	163	79.9	2	1.0	191	93.2	9	4.3	43	20.6
		5-9	404	48	12.0	313	78.3	2	0.5	372	93.0	15	3.7	65	16.2
		10-14	409	47	11.5	347	84.8	1	0.2	387	94.6	25	6.1	67	16.4
		15-20	263	40	15.4	188	72.9	4	1.5	222	86.0	11	4.2	45	17.3
Females	All cases		625	96	15.5	506	82.5	15	2.4	573	93.5	23	3.7	118	19.0
	Age at baseline	<18	62	8	12.9	50	80.6	2	3.2	53	85.5	1	1.6	8	12.9
		18-19	32	5	15.6	26	81.3	1	3.1	30	93.8	3	9.4	10	31.3
		20-24	141	22	15.7	114	82.6	4	2.9	130	94.2	3	2.1	27	19.3
		25-29	159	24	15.3	129	83.8	3	1.9	145	94.2	10	6.4	28	17.8
		30-34	152	27	17.8	128	84.8	4	2.6	147	97.4	5	3.3	35	23.0
		35+	79	10	13.0	59	77.6	1	1.3	68	89.5	1	1.3	10	13.0
	Years since diagnosis	5-9	33	2	6.1	24	72.7	.	.	25	75.8	.	.	5	15.2
		10-14	196	38	19.5	159	82.8	5	2.6	180	93.8	6	3.1	36	18.5
		15-19	231	40	17.5	190	84.1	9	3.9	216	95.6	10	4.4	55	24.1
		20+	165	16	9.8	133	82.1	1	0.6	152	93.8	7	4.3	22	13.4
	Age at diagnosis	<1	9	1	11.1	8	88.9	1	11.1	7	77.8	.	.	1	11.1
		1-4	104	13	12.6	84	82.4	4	3.9	96	94.1	6	5.8	22	21.4
		5-9	175	20	11.4	144	82.8	1	0.6	164	94.3	6	3.4	33	18.9
		10-14	193	34	17.8	155	82.4	6	3.1	177	94.1	7	3.7	33	17.3
		15-20	144	28	19.7	115	82.1	3	2.1	129	92.1	4	2.8	29	20.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Wilms

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases	2070	24	1.2	17	0.8	9	0.4	1917	93.2	3	0.1	140	6.8	
	Age at baseline	<18	761	8	1.1	7	0.9	8	1.1	708	93.3	3	0.4	50	6.6
		18-19	275	3	1.1	2	0.7	1	0.4	258	94.5	.	.	21	7.6
		20-24	611	7	1.1	4	0.7	.	.	582	95.9	.	.	35	5.7
		25-29	342	4	1.2	4	1.2	.	.	300	88.8	.	.	27	7.9
		30-34	66	2	3.1	57	87.7	.	.	5	7.7
		35+	15	12	80.0	.	.	2	13.3
	Years since diagnosis	5-9	167	2	1.2	4	2.4	2	1.2	150	89.8	.	.	21	12.6
		10-14	675	8	1.2	4	0.6	7	1.0	634	94.5	3	0.4	41	6.1
		15-19	679	9	1.3	6	0.9	.	.	651	96.4	.	.	55	8.1
		20+	549	5	0.9	3	0.5	.	.	482	88.6	.	.	23	4.2
	Age at diagnosis	<1	301	2	0.7	4	1.3	2	0.7	251	84.2	1	0.3	9	3.0
		1-4	1261	12	1.0	4	0.3	5	0.4	1195	95.2	1	0.1	72	5.7
		5-9	434	7	1.6	7	1.6	2	0.5	408	94.4	1	0.2	45	10.4
		10-14	54	1	1.9	1	1.9	.	.	45	86.5	.	.	9	17.0
		15-20	20	2	10.0	1	5.0	.	.	18	90.0	.	.	5	25.0
Males	All cases	917	11	1.2	6	0.7	6	0.7	841	92.2	.	.	65	7.1	
	Age at baseline	<18	369	4	1.1	3	0.8	6	1.6	343	93.2	.	.	30	8.1
		18-19	111	1	0.9	1	0.9	.	.	102	91.9	.	.	9	8.1
		20-24	252	3	1.2	1	0.4	.	.	240	96.0	.	.	9	3.6
		25-29	152	2	1.3	1	0.7	.	.	126	84.0	.	.	16	10.5
		30-34	27	1	3.7	24	88.9	.	.	1	3.7
		35+	6	6
	Years since diagnosis	5-9	74	1	1.4	1	1.4	2	2.7	66	89.2	.	.	13	17.6
		10-14	307	3	1.0	2	0.7	4	1.3	287	93.8	.	.	15	4.9
		15-19	289	3	1.0	2	0.7	.	.	277	96.2	.	.	25	8.7
		20+	247	4	1.6	1	0.4	.	.	211	86.5	.	.	12	4.9
	Age at diagnosis	<1	149	1	0.7	2	1.4	1	0.7	121	82.3	.	.	7	4.7
		1-4	564	6	1.1	1	0.2	4	0.7	530	94.5	.	.	33	5.9
		5-9	177	4	2.3	2	1.1	1	0.6	167	94.4	.	.	21	11.9
		10-14	19	.	.	1	5.3	.	.	15	78.9	.	.	2	10.5
		15-20	8	8	.	.	.	2	25.0
Females	All cases	1153	13	1.1	11	1.0	3	0.3	1076	94.0	3	0.3	75	6.5	
	Age at baseline	<18	392	4	1.0	4	1.0	2	0.5	365	93.4	3	0.8	20	5.1
		18-19	164	2	1.2	1	0.6	1	0.6	156	96.3	.	.	12	7.3
		20-24	359	4	1.1	3	0.8	.	.	342	95.8	.	.	26	7.2
		25-29	190	2	1.1	3	1.6	.	.	174	92.6	.	.	11	5.8
		30-34	39	1	2.6	33	86.8	.	.	4	10.5
		35+	9	6	66.7	.	.	2	22.2
	Years since diagnosis	5-9	93	1	1.1	3	3.2	.	.	84	90.3	.	.	8	8.6
		10-14	368	5	1.4	2	0.5	3	0.8	347	95.1	3	0.8	26	7.1
		15-19	390	6	1.5	4	1.0	.	.	374	96.6	.	.	30	7.7
		20+	302	1	0.3	2	0.7	.	.	271	90.3	.	.	11	3.6
	Age at diagnosis	<1	152	1	0.7	2	1.3	1	0.7	130	86.1	1	0.7	2	1.3
		1-4	697	6	0.9	3	0.4	1	0.1	665	95.8	1	0.1	39	5.6
		5-9	257	3	1.2	5	1.9	1	0.4	241	94.5	1	0.4	24	9.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Wilms

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	35	1	2.9	30	90.9	.	.	7	20.6
		15-20	12	2	16.7	1	8.3	.	.	10	83.3	.	.	3	25.0

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Neuroblastoma

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1798	63	3.5	15	0.8	6	0.3	460	25.9	111	6.2	479	26.9
	Age at baseline	<18	889	39	4.4	6	0.7	6	0.7	223	25.4	71	8.0	242	27.4
		18-19	216	4	1.9	1	0.5	.	.	50	23.1	9	4.2	52	24.2
		20-24	504	14	2.8	5	1.0	.	.	129	25.9	21	4.2	148	29.6
		25-29	150	5	3.4	3	2.0	.	.	41	28.1	9	6.1	30	20.5
		30-34	34	1	3.1	17	53.1	1	3.1	6	18.8
		35+	5	1	20.0
	Years since diagnosis	5-9	152	7	4.7	1	0.7	2	1.3	53	35.6	28	18.7	55	36.7
		10-14	558	29	5.2	6	1.1	4	0.7	139	25.0	38	6.8	146	26.2
		15-19	594	15	2.5	1	0.2	.	.	142	24.3	20	3.4	167	28.4
		20+	494	12	2.5	7	1.4	.	.	126	26.0	25	5.1	111	22.8
	Age at diagnosis	<1	912	26	2.9	6	0.7	5	0.6	167	18.5	37	4.1	173	19.1
		1-4	706	28	4.0	9	1.3	1	0.1	231	33.1	59	8.4	242	34.7
		5-9	137	4	3.0	49	36.6	13	9.6	53	39.6
		10-14	27	3	11.5	8	30.8	1	3.8	5	19.2
		15-20	16	2	12.5	5	31.3	1	6.3	6	37.5
Males	All cases		870	28	3.2	8	0.9	3	0.3	219	25.5	50	5.8	248	28.7
	Age at baseline	<18	440	17	3.9	2	0.5	3	0.7	104	23.9	32	7.3	132	30.2
		18-19	94	1	1.1	1	1.1	.	.	25	26.6	6	6.4	22	23.4
		20-24	255	7	2.8	3	1.2	.	.	61	24.3	5	2.0	74	29.4
		25-29	65	2	3.1	2	3.1	.	.	19	29.7	6	9.4	17	26.6
		30-34	14	1	7.1	10	71.4	1	7.1	2	14.3
		35+	2	1	50.0
	Years since diagnosis	5-9	72	3	4.2	1	1.4	1	1.4	22	31.4	13	18.3	27	38.0
		10-14	274	10	3.6	2	0.7	2	0.7	64	23.4	16	5.9	83	30.3
		15-19	283	9	3.2	1	0.4	.	.	71	25.4	11	3.9	80	28.6
		20+	241	6	2.5	4	1.7	.	.	62	26.1	10	4.2	58	24.4
	Age at diagnosis	<1	470	11	2.4	2	0.4	3	0.6	79	16.9	17	3.6	92	19.7
		1-4	317	12	3.8	6	1.9	.	.	107	34.3	26	8.3	120	38.3
		5-9	67	3	4.5	30	46.2	5	7.6	32	48.5
		10-14	10	1	10.0	1	10.0	1	10.0	2	20.0
		15-20	6	1	16.7	2	33.3	1	16.7	2	33.3
Females	All cases		928	35	3.8	7	0.8	3	0.3	241	26.3	61	6.6	231	25.2
	Age at baseline	<18	449	22	4.9	4	0.9	3	0.7	119	26.9	39	8.7	110	24.7
		18-19	122	3	2.5	25	20.5	3	2.5	30	24.8
		20-24	249	7	2.8	2	0.8	.	.	68	27.5	16	6.5	74	29.8
		25-29	85	3	3.6	1	1.2	.	.	22	26.8	3	3.6	13	15.9
		30-34	20	7	38.9	.	.	4	22.2
		35+	3
	Years since diagnosis	5-9	80	4	5.1	.	.	1	1.3	31	39.2	15	19.0	28	35.4
		10-14	284	19	6.7	4	1.4	2	0.7	75	26.4	22	7.7	63	22.3
		15-19	311	6	1.9	71	23.3	9	2.9	87	28.2
		20+	253	6	2.4	3	1.2	.	.	64	25.9	15	6.0	53	21.4
	Age at diagnosis	<1	442	15	3.4	4	0.9	2	0.5	88	20.2	20	4.6	81	18.5
		1-4	389	16	4.1	3	0.8	1	0.3	124	32.2	33	8.5	122	31.7
		5-9	70	1	1.4	19	27.5	8	11.6	21	30.9

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Neuroblastoma

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	2	12.5	7	43.8	.	.	3	18.8
		15-20	10	1	10.0	3	30.0	.	.	4	40.0

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1588	81	5.1	25	1.6	7	0.4	1240	79.2	7	0.4	239	15.2
	Age at baseline	<18	313	22	7.1	4	1.3	3	1.0	268	86.7	4	1.3	68	21.8
		18-19	115	8	7.0	1	0.9	.	.	100	87.7	1	0.9	20	17.5
		20-24	382	17	4.5	6	1.6	2	0.5	317	84.1	2	0.5	80	21.1
		25-29	351	18	5.2	5	1.4	1	0.3	275	79.7	.	.	38	10.9
		30-34	264	10	3.8	8	3.0	.	.	191	72.9	.	.	27	10.3
		35+	163	6	3.8	1	0.6	1	0.6	89	56.0	.	.	6	3.8
	Years since diagnosis	5-9	165	7	4.3	7	4.3	2	1.2	106	65.4	4	2.4	38	23.2
		10-14	473	44	9.3	3	0.6	3	0.6	363	77.9	3	0.6	78	16.6
		15-19	498	20	4.0	7	1.4	.	.	416	84.4	.	.	80	16.1
		20+	452	10	2.2	8	1.8	2	0.4	355	79.8	.	.	43	9.7
	Age at diagnosis	<1	108	4	3.7	.	.	1	0.9	85	79.4	1	0.9	14	13.1
		1-4	507	27	5.4	7	1.4	3	0.6	455	91.0	3	0.6	99	19.7
		5-9	361	18	5.0	9	2.5	.	.	317	88.5	1	0.3	64	17.8
		10-14	311	14	4.6	6	2.0	2	0.7	226	74.1	1	0.3	35	11.4
		15-20	301	18	6.0	3	1.0	1	0.3	157	53.0	1	0.3	27	9.0
Males	All cases		847	46	5.5	12	1.4	5	0.6	687	82.2	4	0.5	137	16.3
	Age at baseline	<18	179	13	7.3	2	1.1	2	1.1	156	87.6	2	1.1	45	25.1
		18-19	58	4	6.9	1	1.7	.	.	52	89.7	1	1.7	9	15.5
		20-24	213	11	5.2	3	1.4	1	0.5	178	85.2	1	0.5	42	19.8
		25-29	179	11	6.2	3	1.7	1	0.6	148	84.1	.	.	22	12.4
		30-34	139	4	2.9	2	1.4	.	.	105	76.6	.	.	17	12.4
		35+	79	3	3.8	1	1.3	1	1.3	48	61.5	.	.	2	2.6
	Years since diagnosis	5-9	89	2	2.2	3	3.4	1	1.1	62	71.3	2	2.2	23	25.8
		10-14	264	32	12.1	2	0.8	3	1.1	210	80.5	2	0.8	54	20.5
		15-19	252	6	2.4	4	1.6	.	.	218	87.9	.	.	40	16.0
		20+	242	6	2.5	3	1.3	1	0.4	197	82.1	.	.	20	8.4
	Age at diagnosis	<1	44	2	4.5	37	84.1	.	.	7	15.9
		1-4	293	14	4.8	4	1.4	2	0.7	263	90.7	2	0.7	54	18.6
		5-9	202	11	5.5	4	2.0	.	.	175	87.9	1	0.5	40	19.9
		10-14	167	10	6.1	2	1.2	2	1.2	129	78.7	1	0.6	25	15.2
		15-20	141	9	6.4	2	1.4	1	0.7	83	59.7	.	.	11	7.8
Females	All cases		741	35	4.8	13	1.8	2	0.3	553	75.8	3	0.4	102	13.9
	Age at baseline	<18	134	9	6.8	2	1.5	1	0.8	112	85.5	2	1.5	23	17.3
		18-19	57	4	7.1	48	85.7	.	.	11	19.6
		20-24	169	6	3.6	3	1.8	1	0.6	139	82.7	1	0.6	38	22.6
		25-29	172	7	4.1	2	1.2	.	.	127	75.1	.	.	16	9.4
		30-34	125	6	4.8	6	4.8	.	.	86	68.8	.	.	10	8.0
		35+	84	3	3.7	41	50.6	.	.	4	4.9
	Years since diagnosis	5-9	76	5	6.7	4	5.3	1	1.3	44	58.7	2	2.7	15	20.0
		10-14	209	12	5.8	1	0.5	.	.	153	74.6	1	0.5	24	11.6
		15-19	246	14	5.7	3	1.2	.	.	198	80.8	.	.	40	16.3
		20+	210	4	1.9	5	2.4	1	0.5	158	77.1	.	.	23	11.2
	Age at diagnosis	<1	64	2	3.2	.	.	1	1.6	48	76.2	1	1.6	7	11.1
		1-4	214	13	6.1	3	1.4	1	0.5	192	91.4	1	0.5	45	21.2
		5-9	159	7	4.4	5	3.1	.	.	142	89.3	.	.	24	15.1
		10-14	144	4	2.8	4	2.8	.	.	97	68.8	.	.	10	7.0
		15-20	160	9	5.7	1	0.6	.	.	74	47.1	1	0.6	16	10.1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All bone

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1931	221	11.5	19	1.0	2	0.1	1018	53.4	4	0.2	380	19.8
	Age at baseline	<18	85	9	10.6	1	1.2	.	.	54	65.1	1	1.2	32	37.6
		18-19	66	12	18.2	40	60.6	.	.	19	28.8
		20-24	359	52	14.5	4	1.1	.	.	204	57.5	1	0.3	97	27.2
		25-29	528	66	12.6	3	0.6	.	.	264	51.0	1	0.2	110	20.9
		30-34	517	59	11.5	8	1.6	1	0.2	261	51.1	1	0.2	74	14.4
		35+	376	23	6.2	3	0.8	1	0.3	195	52.4	.	.	48	12.9
	Years since diagnosis	5-9	214	27	12.7	2	0.9	.	.	110	52.6	.	.	49	23.1
		10-14	629	115	18.4	8	1.3	.	.	309	49.8	2	0.3	140	22.3
		15-19	633	52	8.3	5	0.8	1	0.2	339	54.2	2	0.3	124	19.7
		20+	455	27	6.0	4	0.9	1	0.2	260	57.8	.	.	67	14.8
	Age at diagnosis	<1	8	2	25.0	1	12.5	.	.	7	87.5	.	.	5	62.5
		1-4	80	10	12.5	1	1.3	.	.	57	72.2	1	1.3	28	35.0
		5-9	338	34	10.1	1	0.3	.	.	206	61.5	1	0.3	87	25.7
		10-14	774	83	10.8	6	0.8	1	0.1	399	52.2	1	0.1	151	19.7
		15-20	731	92	12.7	10	1.4	1	0.1	349	48.5	1	0.1	109	15.0
Males	All cases		978	110	11.3	11	1.1	1	0.1	520	53.8	3	0.3	195	20.0
	Age at baseline	<18	43	5	11.6	25	58.1	.	.	14	32.6
		18-19	33	4	12.1	18	54.5	.	.	7	21.2
		20-24	174	20	11.6	100	58.5	1	0.6	49	28.5
		25-29	274	31	11.4	2	0.7	.	.	134	49.8	1	0.4	60	22.0
		30-34	255	37	14.6	6	2.4	.	.	136	54.0	1	0.4	39	15.4
		35+	199	13	6.6	3	1.5	1	0.5	107	54.0	.	.	26	13.1
	Years since diagnosis	5-9	114	12	10.6	56	50.5	.	.	28	24.8
		10-14	318	57	18.0	6	1.9	.	.	153	48.7	1	0.3	64	20.3
		15-19	320	29	9.1	1	0.3	.	.	178	56.0	2	0.6	65	20.4
		20+	226	12	5.3	4	1.8	1	0.4	133	59.6	.	.	38	16.9
	Age at diagnosis	<1	4	4	.	.	.	2	50.0
		1-4	41	7	17.1	29	70.7	.	.	14	34.1
		5-9	173	13	7.5	106	61.6	1	0.6	42	24.3
		10-14	362	31	8.6	4	1.1	.	.	190	53.2	1	0.3	72	20.1
		15-20	398	59	14.9	7	1.8	1	0.3	191	48.7	1	0.3	65	16.4
Females	All cases		953	111	11.7	8	0.8	1	0.1	498	53.0	1	0.1	185	19.6
	Age at baseline	<18	42	4	9.5	1	2.4	.	.	29	72.5	1	2.4	18	42.9
		18-19	33	8	24.2	22	66.7	.	.	12	36.4
		20-24	185	32	17.3	4	2.2	.	.	104	56.5	.	.	48	26.1
		25-29	254	35	13.9	1	0.4	.	.	130	52.2	.	.	50	19.8
		30-34	262	22	8.4	2	0.8	1	0.4	125	48.3	.	.	35	13.5
		35+	177	10	5.7	88	50.6	.	.	22	12.6
	Years since diagnosis	5-9	100	15	15.0	2	2.0	.	.	54	55.1	.	.	21	21.2
		10-14	311	58	18.8	2	0.6	.	.	156	50.8	1	0.3	76	24.4
		15-19	313	23	7.4	4	1.3	1	0.3	161	52.4	.	.	59	19.1
		20+	229	15	6.6	127	55.9	.	.	29	12.8
	Age at diagnosis	<1	4	2	50.0	1	25.0	.	.	3	75.0	.	.	3	75.0
		1-4	39	3	7.7	1	2.6	.	.	28	73.7	1	2.6	14	35.9
		5-9	165	21	12.7	1	0.6	.	.	100	61.3	.	.	45	27.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All bone

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	412	52	12.7	2	0.5	1	0.2	209	51.4	.	.	79	19.3
		15-20	333	33	10.0	3	0.9	.	.	158	48.3	.	.	44	13.4

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Ewings

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		685	78	11.4	5	0.7	1	0.1	613	90.9	4	0.6	251	36.9
	Age at baseline	<18	54	5	9.3	1	1.9	.	.	41	78.8	1	1.9	25	46.3
		18-19	33	5	15.2	26	78.8	.	.	10	30.3
		20-24	157	21	13.5	2	1.3	.	.	139	89.7	1	0.6	64	41.0
		25-29	193	25	13.0	180	94.7	1	0.5	80	41.7
		30-34	153	15	9.9	.	.	1	0.7	140	94.0	1	0.7	47	31.1
		35+	95	7	7.4	2	2.1	.	.	87	91.6	.	.	25	26.3
	Years since diagnosis	5-9	90	6	6.7	1	1.1	.	.	59	67.8	.	.	27	30.3
		10-14	231	43	18.6	1	0.4	.	.	218	95.2	2	0.9	101	43.7
		15-19	214	18	8.5	2	0.9	1	0.5	197	94.3	2	0.9	86	40.8
		20+	150	11	7.3	1	0.7	.	.	139	93.3	.	.	37	24.7
	Age at diagnosis	<1	4	1	25.0	1	25.0	.	.	4	.	.	.	3	75.0
		1-4	50	5	10.0	1	2.0	.	.	44	89.8	1	2.0	20	40.0
		5-9	170	18	10.6	152	90.5	1	0.6	60	35.3
		10-14	257	26	10.2	1	0.4	1	0.4	229	90.9	1	0.4	102	40.2
		15-20	204	28	13.8	2	1.0	.	.	184	91.5	1	0.5	66	32.5
Males	All cases		353	40	11.4	2	0.6	.	.	320	91.4	3	0.9	130	36.9
	Age at baseline	<18	24	3	12.5	19	79.2	.	.	11	45.8
		18-19	17	1	5.9	12	70.6	.	.	3	17.6
		20-24	78	9	11.7	69	90.8	1	1.3	32	41.6
		25-29	99	9	9.1	93	93.9	1	1.0	43	43.4
		30-34	83	13	15.7	79	96.3	1	1.2	27	32.5
		35+	52	5	9.6	2	3.8	.	.	48	92.3	.	.	14	26.9
	Years since diagnosis	5-9	48	1	2.1	30	65.2	.	.	17	36.2
		10-14	109	18	16.5	104	95.4	1	0.9	44	40.4
		15-19	115	13	11.3	1	0.9	.	.	109	94.8	2	1.7	48	41.7
		20+	81	8	9.9	1	1.2	.	.	77	96.3	.	.	21	25.9
	Age at diagnosis	<1	2	2	.	.	.	1	50.0
		1-4	26	5	19.2	25	96.2	.	.	11	42.3
		5-9	84	6	7.1	76	90.5	1	1.2	26	31.0
		10-14	135	13	9.7	121	91.0	1	0.7	54	40.3
		15-20	106	16	15.1	2	1.9	.	.	96	91.4	1	0.9	38	35.8
Females	All cases		332	38	11.5	3	0.9	1	0.3	293	90.4	1	0.3	121	36.8
	Age at baseline	<18	30	2	6.7	1	3.3	.	.	22	78.6	1	3.3	14	46.7
		18-19	16	4	25.0	14	87.5	.	.	7	43.8
		20-24	79	12	15.2	2	2.5	.	.	70	88.6	.	.	32	40.5
		25-29	94	16	17.2	87	95.6	.	.	37	39.8
		30-34	70	2	2.9	.	.	1	1.4	61	91.0	.	.	20	29.4
		35+	43	2	4.7	39	90.7	.	.	11	25.6
	Years since diagnosis	5-9	42	5	11.9	1	2.4	.	.	29	70.7	.	.	10	23.8
		10-14	122	25	20.5	1	0.8	.	.	114	95.0	1	0.8	57	46.7
		15-19	99	5	5.2	1	1.0	1	1.0	88	93.6	.	.	38	39.6
		20+	69	3	4.3	62	89.9	.	.	16	23.2
	Age at diagnosis	<1	2	1	50.0	1	50.0	.	.	2	.	.	.	2	.
		1-4	24	.	.	1	4.2	.	.	19	82.6	1	4.2	9	37.5
		5-9	86	12	14.0	76	90.5	.	.	34	39.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Ewings

				Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	122	13	10.7	1	0.8	1	0.8	108	90.8	.	.	48	40.0
		15-20	98	12	12.4	88	91.7	.	.	28	28.9

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Osteosarcoma

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VP-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1149	136	11.9	14	1.2	1	0.1	348	30.7	.	.	87	7.6
	Age at baseline	<18	25	3	12.0	8	32.0	.	.	2	8.0
		18-19	27	5	18.5	10	37.0	.	.	5	18.5
		20-24	183	31	16.9	2	1.1	.	.	51	28.2	.	.	23	12.7
		25-29	317	40	12.7	3	0.9	.	.	72	23.2	.	.	21	6.6
		30-34	337	41	12.2	8	2.4	.	.	106	31.6	.	.	17	5.1
		35+	260	16	6.3	1	0.4	1	0.4	101	39.5	.	.	19	7.4
	Years since diagnosis	5-9	118	21	17.8	1	0.8	.	.	48	41.4	.	.	19	16.2
		10-14	361	67	18.7	7	1.9	.	.	68	19.2	.	.	19	5.3
		15-19	390	33	8.5	3	0.8	.	.	123	31.8	.	.	25	6.4
		20+	280	15	5.4	3	1.1	1	0.4	109	39.5	.	.	24	8.7
	Age at diagnosis	1-4	21	3	14.3	6	28.6	.	.	1	4.8
		5-9	151	16	10.6	1	0.7	.	.	44	29.3	.	.	20	13.2
		10-14	491	56	11.5	5	1.0	.	.	149	30.7	.	.	37	7.6
		15-20	486	61	12.7	8	1.7	1	0.2	149	31.2	.	.	29	6.0
Males	All cases		577	66	11.5	9	1.6	1	0.2	173	30.5	.	.	45	7.9
	Age at baseline	<18	18	2	11.1	5	27.8	.	.	2	11.1
		18-19	12	2	16.7	4	33.3	.	.	2	16.7
		20-24	86	11	12.8	23	27.1	.	.	12	14.1
		25-29	165	21	12.8	2	1.2	.	.	36	22.5	.	.	12	7.3
		30-34	158	22	14.0	6	3.8	.	.	49	31.4	.	.	7	4.5
		35+	138	8	5.8	1	0.7	1	0.7	56	40.9	.	.	10	7.3
	Years since diagnosis	5-9	64	11	17.2	26	41.3	.	.	10	15.6
		10-14	190	35	18.5	6	3.2	.	.	36	19.4	.	.	8	4.3
		15-19	190	16	8.5	61	32.4	.	.	13	6.9
		20+	133	4	3.0	3	2.3	1	0.8	50	38.2	.	.	14	10.6
	Age at diagnosis	1-4	11	1	9.1	2	18.2	.	.	1	9.1
		5-9	76	7	9.2	22	29.3	.	.	11	14.5
		10-14	220	18	8.2	4	1.8	.	.	64	29.5	.	.	16	7.3
		15-20	270	40	14.9	5	1.9	1	0.4	85	32.1	.	.	17	6.3
Females	All cases		572	70	12.3	5	0.9	.	.	175	30.9	.	.	42	7.4
	Age at baseline	<18	7	1	14.3	3	42.9
		18-19	15	3	20.0	6	40.0	.	.	3	20.0
		20-24	97	20	20.6	2	2.1	.	.	28	29.2	.	.	11	11.5
		25-29	152	19	12.7	1	0.7	.	.	36	24.0	.	.	9	5.9
		30-34	179	19	10.6	2	1.1	.	.	57	31.8	.	.	10	5.6
		35+	122	8	6.7	45	37.8	.	.	9	7.6
	Years since diagnosis	5-9	54	10	18.5	1	1.9	.	.	22	41.5	.	.	9	17.0
		10-14	171	32	18.9	1	0.6	.	.	32	18.9	.	.	11	6.4
		15-19	200	17	8.5	3	1.5	.	.	62	31.2	.	.	12	6.0
		20+	147	11	7.6	59	40.7	.	.	10	6.9
	Age at diagnosis	1-4	10	2	20.0	4	40.0
		5-9	75	9	12.0	1	1.3	.	.	22	29.3	.	.	9	12.0
		10-14	271	38	14.1	1	0.4	.	.	85	31.6	.	.	21	7.8
		15-20	216	21	9.9	3	1.4	.	.	64	30.2	.	.	12	5.6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included